Prospects for a personalized peptide vaccine against lung cancer

References

• Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000 Feb 5;355(9202):479–485. PMID:10841143.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 Jul 9;373(2):123–135. PMID:26028407 PMCID:PMC4681400.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627–1639. PMID:26412456 PMCID:PMC5705936.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550. PMID:26712084.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823–1833. Epub 2016 Oct 8. PMID:27718847.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 Jan 21;389(10066):255–265.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017 Nov 16;377(20):1919–1929. PMID:28885881.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018 Dec 13;379(24):2342–2350. PMID:30280658.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040–2051. PMID:30280635.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078–2092. PMID:29658856.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018 Jun 14;378(24):2288–2301. PMID:29863955.
   PubMed Web of Science ®Google Scholar
• Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992 Nov 1;176(5):1453–1457. PMID:1402688.
   PubMed Web of Science ®Google Scholar
• Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991 Dec 13;254(5038):1643–1647. PMID:1840703.
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011 Dec 21;480(7378):480–489. PMID: 22193102.
   PubMed Web of Science ®Google Scholar
• Bezu L, Kepp O, Cerrato G, et al. Trial watch: peptide-based vaccines in anticancer therapy. Oncoimmunology. 2018 Sep 6;7(12):e1511506. PMID: 30524907.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004 Sep;10(9):909–915. PMID: 15340416.
   PubMed Web of Science ®Google Scholar
• Wada S, Yada E, Ohtake J, et al. personalized peptide vaccines for cancer therapy: current progress and state of the art. Expert Rev Precis Med Drug Dev. 2017;2:6,371–381.
   Web of Science ®Google Scholar
• Sasada T, Noguchi M, Yamada A, et al. Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer. Hum Vaccin Immunother. 2012 Sep;8(9):1309–1313. PMID:22894962.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015 Apr 3;348(6230):69–74. PMID:25838375.
   PubMed Web of Science ®Google Scholar
• Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018 Mar 23;359(6382):1355–1360. PMID:29567706.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009 Sep 1;15(17):5323–5337. PMID: 19723653 PMCID: PMC5779623.
   PubMed Web of Science ®Google Scholar
• Abrams SI, Dobrzanski MJ, Wells DT, et al. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. Eur J Immunol. 1995 Sep;25(9):2588–2597. PMID:7589131.
   PubMed Web of Science ®Google Scholar
• Chen W, Peace DJ, Rovira DK, et al. T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1468–1472. PMID:1346932 PMCID:PMC48472.
   PubMed Web of Science ®Google Scholar
• Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci. 2006 Oct;97(10):970–976. PMID:16984371.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother. 2013 May;62(5):919–929. PMID:23197273.
   PubMed Web of Science ®Google Scholar
• Sakamoto S, Noguchi M, Yamada A, et al. Prospect and progress of personalized peptide vaccinations for advanced cancers. Expert Opin Biol Ther. 2016;16(5):689–698. PMID:26938083.
   PubMed Web of Science ®Google Scholar
• Sasada T, Yamada A, Noguchi M, et al. Personalized peptide vaccine for treatment of advanced cancer. Curr Med Chem. 2014;21(21):2332–2345. PMID:24524766.
   PubMed Web of Science ®Google Scholar
• Nakao M, Yamana H, Imai Y, et al. HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res. 1995 Oct 1;55(19):4248–4252. PMID:7671230.
   PubMed Web of Science ®Google Scholar
• Nishizaka S, Gomi S, Harada K, et al. A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma. Cancer Res. 2000 Sep;60(17):4830–4837. PMID:10987294.
   PubMed Web of Science ®Google Scholar
• Shichijo S, Nakao M, Imai Y, et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med. 1998 Feb 2;187(3):277–288. PMID:9449708 PMCID:PMC2212124.
   PubMed Web of Science ®Google Scholar
• Yamada A, Kawano K, Harashima N, et al. Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer. Cancer Immunol Immunother. 1999 May-Jun;48(2–3):147–152. PMID:10414469.
   PubMed Web of Science ®Google Scholar
• Yang D, Nakao M, Shichijo S, et al. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res. 1999 Aug 15;59(16):4056–4063. PMID:10463607.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Moriya F, Koga N, et al. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother. 2016 Feb;65(2):151–160. PMID:26728480.
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Minami T, Nozawa M, et al. A phase 2 randomized controlled trial of personalized peptide vaccine immunotherapy with low-dose dexamethasone versus dexamethasone alone in chemotherapy-naive castration-resistant prostate cancer. Eur Urol. 2016 Jul;70(1):35–41. PMID:26782346.
   PubMed Web of Science ®Google Scholar
• Yanagimoto H, Shiomi H, Satoi S, et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep. 2010 Sep;24(3):795–801. PMID:20664989.
   PubMed Web of Science ®Google Scholar
• Yutani S, Komatsu N, Yoshitomi M, et al. A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. Oncol Rep. 2013 Sep;30(3):1094–1100. PMID:23784011.
   PubMed Web of Science ®Google Scholar
• Shirahama T, Muroya D, Matsueda S, et al. A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer. Cancer Sci. 2017 May;108(5):838–845. PMID:28188670.
   PubMed Web of Science ®Google Scholar
• Yoshitomi M, Yutani S, Matsueda S, et al. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med. 2012 Mar;3(3):463–469. PMID:22969912.
   PubMed Web of Science ®Google Scholar
• Terasaki M, Shibui S, Narita Y, et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen–A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol. 2011 Jan 20;29(3):337–344. PMID:21149665.
   PubMed Web of Science ®Google Scholar
• Kibe S, Yutani S, Motoyama S, et al. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer. Cancer Immunol Res. 2014 Dec;2(12):1154–1162. PMID:25351849.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Matsumoto K, Uemura H, et al. An open-label, randomized phase II trial of personalized peptide vaccination in patients with bladder cancer that progressed after platinum-based chemotherapy. Clin Cancer Res. 2016 Jan 1;22(1):54–60. PMID:26581246.
   PubMed Web of Science ®Google Scholar
• Suekane S, Ueda K, Nishihara K, et al. Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma. Cancer Sci. 2017 Dec;108(12):2430–2437. PMID:28940789.
   PubMed Web of Science ®Google Scholar
• Yamada T, Terazaki Y, Sakamoto S, et al. Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens. Int J Oncol. 2015 Jan;46(1):55–62. PMID:25310280.
   PubMed Web of Science ®Google Scholar
• Yoshiyama K, Terazaki Y, Matsueda S, et al. Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol. 2012 May;40(5):1492–1500. PMID:22307435.
   PubMed Web of Science ®Google Scholar
• Takayama K, Sugawara S, Saijo Y, et al. Randomized phase II study of docetaxel plus personalized peptide vaccination versus docetaxel plus placebo for patients with previously treated advanced wild type EGFR non-small-cell lung cancer. J Immunol Res. 2016;2016:1745108. PMID:27274999 PMCID:PMC4870343.
   PubMed Web of Science ®Google Scholar
• Terazaki Y, Yoshiyama K, Matsueda S, et al. Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer. Cancer Sci. 2012 Apr;103(4):638–644. PMID:22321067.
   PubMed Web of Science ®Google Scholar
• Sakamoto S, Yamada T, Terazaki Y, et al. Feasibility study of personalized peptide vaccination for advanced small cell lung cancer. Clin Lung Cancer. 2017 Nov;18(6):e385–e394. PMID:28416261.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Snyder A. Making it personal: neoantigen vaccines in metastatic melanoma. Immunity. 2017 Aug 15;47(2):221–223. PMID:28813655.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 Jul 13;547(7662):217–221. PMID:28678778 PMCID:PMC5577644.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017 Jul 13;547(7662):222–226. PMID:28678784.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 Apr 3;348(6230):124–128. Mar 12. PMID:25765070.
   PubMed Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017 Jun 22;376(25):2415–2426. PMID:28636851.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018 May 31;378(22):2093–2104. PMID:29658845.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786–792.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.
   PubMed Web of Science ®Google Scholar
• Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl 1):S24–31.
   PubMedGoogle Scholar
• Oxnard GR, Arcila ME, Chmielecki J, et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res. 2011;17:5530–5537.
   PubMed Web of Science ®Google Scholar
• Ayoola A, Barochia A, Belani K, et al. Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest. 2012;30:433–446.
   PubMed Web of Science ®Google Scholar
• Yamada T, Azuma K, Muta E, et al. EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation. PLoS One. 2013 Nov 5;8(11):e78389.
   PubMed Web of Science ®Google Scholar
• Ofuji K, Tada Y, Yoshikawa T, et al. A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer. Int J Oncol. 2015 Feb;46(2):497–504. PMID: 25532027.
   PubMed Web of Science ®Google Scholar
• Karasaki T, Nagayama K, Kawashima M, et al. Identification of individual cancer-specific somatic mutations for neoantigen-based immunotherapy of lung cancer. J Thorac Oncol. 2016 Mar;11(3):324–333. PMID:26752676.
   PubMed Web of Science ®Google Scholar
• Cai W, Zhou D, Wu W, et al. MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design. BMC Genomics. 2018 Aug 3;19(1):582. PMID:30075702 PMCID:PMC6090856.
   PubMed Web of Science ®Google Scholar
• Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1: PD-L1pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013 Mar 15;73(6):1733–1741. PMID: 23288508.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016 May;16(5):275–287. PMID: 27079802.
   PubMed Web of Science ®Google Scholar
• Karyampudi L, Lamichhane P, Scheid AD, et al. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res. 2014 Jun 1;74(11):2974–2985. PMID: 24728077.
   PubMed Web of Science ®Google Scholar
• Petrizzo A, Mauriello A, Luciano A, et al. Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. Oncotarget. 2017 Dec 8;9(3):3576–3589. PMID: 29423067.
   PubMedGoogle Scholar
• Massarelli E, William W, Johnson F, et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncol. 2019 Jan 1;5(1):67–73. PMID:30267032.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014 Dec 4;371(23):2189–2199. PMID: 25409260.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 2015 Jan;5(1):16–18. PMID:25583798.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015 Apr 3;348(6230):56–61. PMID:25838373.
   PubMed Web of Science ®Google Scholar
• Perea F, Bernal M, Sánchez-Palencia A, et al. The absence of HLA class I expressionin non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration. Int J Cancer. 2017 Feb 15;140(4):888–899. PMID: 27785783.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Rosenthal R, Hiley CT, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017 Nov 30;171(6):1259–1271. PMID: 29107330.
   PubMed Web of Science ®Google Scholar